<DOC>
	<DOCNO>NCT02414958</DOCNO>
	<brief_summary>Comparison 2 dos empagliflozin vs placebo patient already use either insulin regimen MDI CSII . Randomisation 3 treatment arm ( equal assignment ) follow screen period , optimisation period run-in period . 52 week double-blind treatment period , 3 week follow-up period .</brief_summary>
	<brief_title>Empagliflozin Adjunctive inSulin thErapy Type 1 Diabetes Over 52 Weeks ( EASE-2 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criterion : Male female patient receive insulin treatment document diagnosis T1DM least 1 year time Visit 1 Fasting Cpeptide value &lt; 0.7 ng/mL ( 0.23 nmol/L ) Visit 2 measure central laboratory Use , willing , base Investigator 's judgement , continue throughout duration trial , either : MDI insulin consist least one basal insulin injection least three daily bolus injection OR CSII insulin type , least 5 month experience use CSII prior Visit 1 HbA1c &gt; /= 7.5 % &lt; /= 10.0 % Visit 5 measure central laboratory Age &gt; /= 18 year Visit 1 Additional inclusion criterion may apply Exclusion criterion : History T2DM , maturity onset diabetes young ( MODY ) , pancreatic surgery chronic pancreatitis Pancreas , pancreatic islet cell renal transplant recipient T1DM treatment antihyperglycaemic drug ( e.g . metformin , alphaglucosidase inhibitor , GLP1 analogues , SGLT2 inhibitor , pramlintide , inhaled insulin , premixed insulin etc . ) except subcutaneous basal bolus insulin within 3 month prior Visit 1 Occurrence severe hypoglycaemia involve coma/unconsciousness and/or seizure require hospitalisation hypoglycaemiarelated treatment emergency physician paramedic within 3 month prior Visit 1 randomisation Occurence DKA within 3 month prior Visit 1 randomisation Additional exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>